This study is testing a new medication called VX-581, which is given as a liquid by mouth. Researchers want to understand how safe VX-581 is, how well your body tolerates it, and how it moves through your system. They are testing VX-581 alone and in combination with other cystic fibrosis medications, tezacaftor (TEZ) and deutivacaftor (D-IVA). This study is looking for healthy volunteers between 18 and 55 years old. The main goal is to track any side effects (adverse events) that participants might experience. The study is currently unclear on its recruitment status and plans to enroll 136 participants.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It involves different parts where VX-581 is given alone or with other medications, or a placebo (an inactive substance).

What's involved

You would go through a screening phase, a treatment phase where you receive the study medication for up to 10 days, and a safety follow-up phase.

Compensation

Not stated in the trial record.

Follow-up

Safety will be monitored for up to 8 days after the last dose in Part A, and up to 17 days after the last dose in Parts B and C.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.